VenBio Partners — Pre-Seed & Growth VC Firm ($2.0M–$5.0M Checks)
VenBio Partners is a Pre-Seed, Growth venture capital firm based in San Francisco, CA investing in Healthcare. The firm typically writes $2.0M–$5.0M checks and has 44 portfolio companies in our records.
- Check size
- $2.0M–$5.0M
- Portfolio
- 44 companies on record
- Partners
- 4 listed
- AUM
- $2B
- Stage
- Pre-Seed, Growth
- Sectors
- Healthcare
- HQ
- San Francisco, CA
Last verified: 2026-06-06
Pre-Seed, Growth
$2.0M – $5.0M
$2.0B
44+ companies
4 partners
About VenBio Partners
VenBio Partners is a venture capital firm headquartered in San Francisco, California. The firm invests in life sciences and biotech companies that focus on transformative therapies addressing large unmet medical needs.
VenBio Partners participates in early and growth stage investments within the healthcare and pharmaceuticals sectors, with a particular interest in pain management. Typical check sizes range from $2.0 million to $5.0 million. The firm has assets under management of $2 billion and prefers to be approached via warm introduction.
Investment Thesis
venBio invests in life sciences and biotech companies that focus on transformative therapies addressing large unmet medical needs.
How VenBio Partners invests
VenBio Partners is a vc firm based in San Francisco, CA. The firm invests at the Pre-Seed, Growth stages, with a focus on Healthcare.
VenBio Partners typically writes checks of $2.0M–$5.0M per investment, backed by approximately $2B in assets under management.
VenBio Partners has backed 44 companies in our records, including Alector, Apellis Pharmaceuticals, Candid Therapeutics.
Partners & Team
Industry Focus
Invests In
Recent Activity
Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome
Jun 2026 · venBio
Achieve Life Sciences Announces Up to $354 Million Private Placement
Apr 2026 · venBio
venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies
Jan 2026 · venBio
Investment Track Record
VenBio Partners has recorded investments in 44 portfolio companies. The firm has participated in financings for Achieve Life Sciences in the biopharma sector as well as multiple acquisitions by major pharmaceutical companies including Alumis, AstraZeneca, Bayer, Biogen, Bristol Myers Squibb, Eli Lilly and Company, Genentech/Roche, GSK, Johnson & Johnson, Lyell Immunopharma Inc, Merck, Novo Nordisk, Regeneron, and Sanofi.
These recorded investments reflect the firm's focus on healthcare, pharmaceuticals, and pain management across early and growth stages.
Portfolio Companies (44)
Other
Alector
Apellis Pharmaceuticals
Candid Therapeutics
Vicebio
Pharvaris
ACQ by GSK
ACQ by Bristol Myers Squibb
ACQ by Alumis
NASDAQ: ACHV
NASDAQ: AKRO
- •Raising at Pre-Seed, Growth? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare — the sectors they actively back.
- •Size your ask to their typical $2.0M – $5.0M check.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Corey Goodman, Managing Partner.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if VenBio Partners is a match for your startup
Upload your pitch deck to see how well you match with VenBio Partners and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal